3 Reasons I Just Bought Fulgent Genetics Stock
With U.S. cases of COVID-19 down more than 90% from their January peak, it might seem like an odd time to invest in a company that attributes more than 90% of last year's business to testing for the disease. Unfortunately, several new strains of the virus that cause COVID-19 have been spreading. That could mean the end of the pandemic is a lot farther away than many believe.
One company playing multiple roles in the fight is Fulgent Genetics (NASDAQ: FLGT), which saw both testing volumes and its stock price explode higher last year. Even after this run-up, there are at least three reasons shares could still beat the market over the next few years.
Image source: Getty Images.
Source Fool.com
